Hemostemix (CVE:HEM) Shares Down 22.9% – What’s Next?

Hemostemix Inc. (CVE:HEM) was down 22.9% on Friday . The company traded as low as C$0.18 and last traded at C$0.19. Approximately 504,239 shares traded hands during mid-day trading, a decline of 5% from the average daily volume of 530,580 shares. The stock had previously closed at C$0.24.

Hemostemix Stock Down 22.9 %

The company has a quick ratio of 0.48, a current ratio of 0.04 and a debt-to-equity ratio of -55.07. The business has a 50-day simple moving average of C$0.19 and a 200-day simple moving average of C$0.11. The company has a market cap of C$26.96 million, a PE ratio of -5.39 and a beta of 0.20.

Hemostemix Company Profile

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.